Evaluation of Selected Flavonoids as Antiangiogenic, Anticancer, and Radical Scavenging Agents: An Experimental and In Silico Analysis

Cell Biochemistry and Biophysics

Volumn 61, Issue 3, 2011, Pages 651-663

  Gacche, Rajesh N ^a   Shegokar, Harshala D ^a   Gond, Dhananjay S ^a   Yang, Zhenzhou ^a,b   Jadhav, Archana D ^a  

^a SWAMI RAMANAND TEERTH MARATHWADA UNIVERSITY   (India)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Anticancer; Flavonoids; Free radicals; In silico analysis

Indexed keywords

1,1 DIPHENYL 2 PICRYLHYDRAZYL; 2,2-DIPHENYL-1-PICRYLHYDRAZYL; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BIPHENYL DERIVATIVE; FLAVONOID; PICRIC ACID; SCAVENGER; SUPEROXIDE;

ARTICLE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG SCREENING; HUMAN; ISOMERISM; KINETICS; METABOLISM; PROTEIN CONFORMATION; QUANTUM THEORY; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BIPHENYL COMPOUNDS; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DRUG EVALUATION, PRECLINICAL; FLAVONOIDS; FREE RADICAL SCAVENGERS; HUMANS; ISOMERISM; KINETICS; MODELS, MOLECULAR; PICRATES; PROTEIN CONFORMATION; QUANTUM THEORY; STRUCTURE-ACTIVITY RELATIONSHIP; SUPEROXIDES;

TETRA;

EID: 81155131029     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-011-9251-z     Document Type: Article

References (63)

1. Auerbach, R., Lewis, R., Shinners, B., Kubai, L., & Akhtar, N. (2003). Angiogenesis assays: A critical overview. Clinical Chemistry, 49(1), 32-40.
2. Carmeliet, P. (2005). Angiogenesis in life, disease and medicine. Nature, 42, 932-936.
3. Plate, K. H., Breier, G., Weich, H. A., & Risau, W. (1992). Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature, 359, 845-848.
4. Ferrara, N., & Davis-Smyth, T. (1997). The biology of vascular endothelial growth factor. Endocrine Reviews, 18, 4-25.
5. Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249-257.
6. Brekken, R. A., Overholser, J. P., Stastny, V. A., Waltenberger, J., Minna, J. D., & Thorpe, P. E. (2000). Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activities by a monoclonal anti-VEGF antibody blocks tumor growth in mice. Cancer Research, 60, 5117-5124.
7. Borgstrom, P., Bourdon, M. A., Hillan, K. J., Sriramarao, P., & Ferrara, N. (1998). Neutralizing anti-vascular endothelial growth factor antibody completely inhibits angiogenesis and growth of human prostate carcinoma micro tumors in vivo. Prostate, 35, 1-10.
8. Angelov, L., Salhia, B., Roncari, L., McMahon, G., & Guha, A. (1999). Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Research, 59, 5536-5541.
9. Zhong, H., De Marzo, A. M., Laughner, E., Lim, M., Hilton, D. A., Zagzag, D., et al. (1999). Overexpression of hypoxia-inducible factor-1 alpha in common human cancers and their metastases. Cancer Research, 59, 5830-5835.
10. Maxwell, P. H., Dachs, G. U., Gleadle, J. M., Nicholls, L. G., Harris, A. L., Stratford, I. J., et al. (1997). Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 94, 8104-8109.
11. Singh, R., Singh, R. K., Mahdi, A. A., Misra, S., Rai, S. P., Singh, D., et al. (1998). Studies on circadian periodicity of urinary corticoids in carcinoma of the breast. In Vivo, 2(1), 69-73.
12. Singh, R., Singh, R. K., Mahdi, A. A., Singh, R. K., Kumar, A. K., Tripathi, A., et al. (2003). Circadian periodicity of plasma lipid peroxides and other antioxidants as putative markers in gynecological malignancies. In Vivo, 17, 593-600.
13. Romero, I., Paez, A., Femelo, A., Lujan, M., & Berenguer, A. (2002). Polyphenols in red wine inhibit the proliferation and induce apoptosis of LNCaP cells. British Journal of Urology International, 89, 950-954.
14. Choi, Y. H., Zhang, L., Lee, W. H., & Park, K. Y. (1998). Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. International Journal of Oncology, 13, 391-396.
15. Davis, J. N., Singh, B., Bhuiyan, M., & Sarkar, F. H. (1998). Genistein-induced upregulation of p21 WAF1, downregulation of cyclin B and induction of apoptosis in prostate cancer cells. Nutrition and Cancer, 32, 123-131.
16. Lian, F., Bhuiyan, M., Li, Y. M., Wall, N., Kraut, M., & Sarkar, F. H. (1998). Genistein-induced G2-M arrest, p21WAF1 upregulation and apoptosis in a nonsmall-cell lung cancer cell line. Nutrition and Cancer, 31, 184-191.
17. Matsukawa, Y., Mami, N., Sakai, T., Satomi, Y., Yoshida, M., Matsumoto, K., et al. (1993). Genistein arrests cell cycle progression at G2-M. Cancer Research, 53, 1328-1331.
18. Middleton, E., Kandaswami, C., & Theoharides, T. C. (2000). The effects of plant flavonoids on mammalian cells: Implications for inflammation, heart disease, and Cancer. Pharmacological Reviews, 52, 673-751.
19. Fotsis, T., Pepper, M. S., Aktas, E., Breit, S., Rasku, S., Adlerkreutz, H., et al. (1997). Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Research, 57, 2916-2921.
20. Gacche, R., Shegokar, H., Gond, D., Jadhav, A., & Ghole, V. (2010). Effect of hydroxyl substitution of flavone on angiogenesis and free radical scavenging activities: A structure-activity relationship studies using computational tools. European Journal of Pharmaceutical Sciences, 39, 37-44.
21. Park, K., Lim, D., Park, S. D., Kim, M. Y., & Kim, Y. (2004). Angiogenesis inhibitor derived from angiostatin active sites. Bulletin of the Korean Chemical Society, 25(9), 1331-1335.
22. Soucy, N. V., Ihnat, M. A., Kamat, C. D., Hess, L., Mark, J. P., Klei, L. R., et al. (2003). Arsenic stimulates angiogenesis and tumorigenesis in vivo. Toxicological Sciences, 76, 271-279.
23. Qui{dotless}ntero, A., Pelcastre, A., & Solano, J. D. (1999). Antitumoral activity of new pyrimidine derivatives of sesquiterpene lactones. Journal of Pharmaceutical Sciences, 2, 108-112.
24. Mantani, N., Imanishii{dotless}, N., Kawamata, H., Terasawa, K., & Ochiai, H. (2001). Inhibitory effect of (+)-catechin on the growth of influenza A/PR/8 virus in MDCK cells. Planta Medica, 67, 240-243.
25. Mosmann, T. (1983). Rapid colorimetric assay for cellular grow and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55-63.
26. Kawase, M., Motohashi, N., Satoh, K., Sakagami, H., Nakashima, H., Tani{dotless}, S., et al. (2003). Biological activity of Persimmon (Diospyros kaki) peel extracts. Phytotherapy Research, 17, 495-500.
27. Liu, F. V., Ooi, E. C., & Chang, S. T. (1997). Free radical scavenging activity of mushroom polysaccharide extract. Life Sciences, 60, 763-771.
28. Gacche, R. N., Dhole, N. A., Kamble, S. G., & Bandgar, B. P. (2007). In vitro evaluation of selected chalcones for antioxidant activity. Journal of Enzyme Inhibition and Medicinal Chemistry, 23(1), 28-31.
29. Thompson, M. A. (2004). ArgusLab 4. 0. 1. Seattle, WA: Planaria Software LLC.
30. Wiesmann, C., Christinger, H. W., Cochran, A. G., Cunningham, B. C., Fairbrother, W. J., Keenan, C. J., et al. (1998). Crystal structure of the complex between VEGF and a receptor-blocking peptide. Biochemistry, 37, 17765-17772.
31. McDonough, M. A., McNeill, L. A., Tilliet, M., Papamicael, C. A., Chen, Q. Y., Banerji, B., et al. (2005). Selective inhibition of factor inhibiting hypoxia-inducible factor. Journal of the American Chemical Society, 127, 7680-7681.
32. Miyazaki, Y., Matsunaga, S., Tang, J., Maeda, Y., Nakano, M., Philippe, R. J., et al. (2005). Novel 4-amino-furo [2, 3-d] pyrimidines as Tie-2 and VEGFR2 dual inhibitors. Bioorganic and Medicinal Chemistry Letters, 15, 2203-2207.
33. Staton, C. A., Stribbling, S. M., Tazzyman, S., Hughes, R., Brown, N. J., & Lewis, C. E. (2004). Current methods for assaying angiogenesis in vitro and in vivo. International Journal of Experimental Pathology, 85, 233-248.
34. Chan, T. S., Galati, G., Pannala, A. S., Rice-Evans, C., & O'Brien, P. J. (2003). Simultaneous detection of the antioxidant and pro-oxidant activity of dietary polyphenolics in a peroxidase system. Free Radical Research, 37, 787-794.
35. Nijveldt, R. J., Nood, E., Hoorn, D. E. C., Boelens, P. G., Norren, K., & Leeuwen, P. A. M. (2001). Flavonoids: a review of probable mechanisms of action and potential applications. American Journal of Clinical Nutrition, 74, 418-425.
36. Kim, M. H. (2003). Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases. Journal of Cellular Biochemistry, 89(3), 529-538.
37. Yuki, H., Kiyoshi, E., Yoko, Y., Setsuko, K., Yasuaki, H., Yoshiteru, I., et al. (2003). Specific inhibition of hypoxia-inducible factor (HIF)-1a activation and vascular endothelial growth factor (VEGF) production by flavonoids. Biological and Pharmaceutical Bulletin, 26(10), 1379-1383.
38. Lee, J. Y., Jeong, K. W., Kim, W., Heo, Y. S., & Kim, Y. (2009). Binding models of flavonols to human vascular endothelial growth factor receptor 2. Bulletin of the Korean Chemical Society, 30(9), 2083-2086.
39. Mojzis, J., Varinska, L., Mojzisova, G., Kostova, I., & Mirossay, L. (2008). Antiangiogenic effects of flavonoids and chalcones. Pharmacological Research, 57(4), 259-265.
40. Chahar, M. K., Sharma, N., Dobhal, M. P., & Joshi, Y. C. (2011). Flavonoids: A versatile source of anticancer drugs. Pharmacognosy Reviews, 5, 1-12.
41. Kuntz, S., Wenzel, U., & Daniel, H. (2009). Comparative analysis of the effects of flavonoids on proliferation, cytotoxicity and apoptosis in human colon cancer cell lines. European Journal Nutrition, 38, 133-142.
42. Katyal, S., Gao, Z., Liu, R. Z., & Godbout, R. (2007). Evolutionary conservation of alternative splicing in chicken. Cytogenetic and Genome Research, 117, 146-157.
43. Camenisch, G., Tini, M., Chilov, D., Kvietikova, I., Srinivas, V., Caro, J., et al. (1999). General applicability of chicken egg yolk antibodies: the performance of IgY immunoglobulins raised against the hypoxia inducible factor 1α. FASEB Journal, 13, 81-88.
44. Jones, P. F., McClain, J., Robinson, D. M., Seto, T. N., & Yancopoulos, G. D. (1999). Identification and characterization of chicken cDNAs encoding the endothelial cell-specific receptor tyrosine kinase Tie2 and its ligands, the angiopoietins. Angiogenesis, 2(4), 357-364.
45. Shibuya, M. (2002). Vascular endothelial growth factor receptor family gene: When did the three genes phylogenetically segregate? Journal of Biological Chemistry, 383(10), 1573-1579.
46. Schweigerer, L., Christeleit, K., Fleischmann, G., Adlercreutz, H., Wahala, K., Hase, T., et al. (1992). Identification in human urine of a natural growth inhibitor for cells derived from solid pediatric tumors. European Journal of Clinical Investigation, 22, 260-264.
47. Fang, J., Xia, C., Cao, Z., Zheng, J. Z., Reed, E., & Jiang, B. H. (2005). Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/p70S6K1 and HDM2/p53 pathways. FASEB Journal, 19, 342-353.
48. Fu, B., Xue, J., Li, Z., Shi, X., Jiang, B. H., & Fang, J. (2007). Chrysin inhibits expression of hypoxia-inducible factor-1A through reducing hypoxia-inducible factor-1A stability and inhibiting its protein synthesis. Molecular Cancer Therapeutics, 6(1), 221-226.
49. Korkina, L. G., & Afanasev, I. B. (1997). Antioxidant and chelating properties of flavonoids. Advances in Pharmacology, 38, 151-163.
50. Hanasaki, Y., Ogawa, S., & Fukui, S. (1994). The correlation between active oxygens scavenging and antioxidative effects of flavonoids. Free Radical Biology and Medicine, 16, 845-850.
51. Farkas, O., Jakus, J., & Héberger, J. (2004). Quantitative structure-antioxidant activity relationships of flavonoid compounds. Molecules, 9, 1079-1088.
52. Rice-Evans, C. A., Miller, N. J., & Paganga, G. (1996). Structure-antioxidant activity relationship of flavonoids and phenolic acids. Free Radical Biology and Medicine, 20(7), 933-956.
53. Pannala, A. S., Chan, T. S., O'Brien, P. J., & Rice-Evans, C. A. (2001). Flavonoid B-ring chemistry and antioxidant activity: Fast reaction kinetics. Biochemical and Biophysical Research Communications, 282, 1161-1168.
54. Burda, S., & Oleszek, W. (2001). Antioxidant and antiradical activities of flavonoids. Journal of Agricultural and Food Chemistry, 49, 2774-2779.
55. Kanadaswami, C., Lee, L.-T., & Lee, P.-P. (2005). The antitumor activities of flavonoids. In Vivo, 19(5), 895-909.
56. Yuan, Z. P., Chen, L. J., & Fan, L. Y. (2006). Liposomal quercetin efficiently suppresses growth of solid tumors in murine models. Clinical Cancer Research, 12(10), 3193-3199.
57. Karelson, M., & Lobanov, V. S. (1996). Quantum-chemical descriptors in QSAR/QSPR studies. Chemical Reviews, 96, 1027-1043.
58. Gacche, R., Khsirsagar, M., Kamble, S., Bandagar, B., Dhole, N., Shisode, K., et al. (2008). Antioxidant and anti-inflammatory related activities of selected synthetic chalcones: Structure-activity relationship studies using computational tools. Chemical and Pharmaceutical Bulletin, 56(7), 897-901.
59. Honorio, K. M., & Da Silva, A. B. F. (2003). An AM1 study on the electron-donating and electron accepting character of biomolecules. International Journal of Quantum Chemistry, 95(2), 126-132.
60. Tuppurainen, K., Lotjonen, S., Laatikainen, R., Vartiainen, T., Maran, U., Strandberg, M., et al. (1991). About the mutagenicity of chlorine-substituted furanones and halopropenals-a QSAR study using molecular orbital indexes. Mutation Research, 247, 97-202.
61. Pearson, R. G., & Songstad, J. (1967). Application of the principle of hard and soft acids and bases to organic chemistry. Journal of the American Chemical Society, 89, 1827-1836.
62. Vemulapalli V, Ghilzai NM, Jasti BR (2007) Physicochemical characteristics that influence the transport of drugs across intestinal barrier. AAPS Newsmagazine 18.
63. Wang, J., Hou, T., & Xu, X. (2009). Aqueous solubility prediction based on weighted atom type counts and solvent accessible surface areas. Journal of Chemical Information and Modelling, 49, 571-581.